What distinguishes EVI from other companies in the Peripheral Vascular Surgery space?
EndoVascular Instruments (EVI) has the only Peripheral Vascular Surgery device that can remove failed stents with a minimally invasive procedure. (DSA – De-Stenting the Artery)

What is the primary focus of EVI's kit of surgical devices, and which patient population does it specifically aim to treat?
EVI manufactures a kit of surgical devices designed to treat patients with late-stage Peripheral Artery Disease (PAD).

What does the EVI kit allow surgeons to do?
The EVI kit removes plaque and/or failed stents using a minimally invasive procedure followed by inserting a stent/graft to prevent restenosis.

What is the estimated market size for the EVI?
The market for the EVI kit is $10.4B in the US and $16B globally.

Can you provide insights into the insurance reimbursement landscape for the EVI Kit?
The EVI Kit has an already existing insurance reimbursement code, 37227.

What regulatory pathway is EVI pursuing?
EVI is seeking FDA approval through the 510K route, with no human clinical data required.